BioCentury
ARTICLE | Company News

4SC, Menarini deal

April 27, 2015 7:00 AM UTC

4SC granted Menarini exclusive rights to develop and commercialize resminostat to treat cancer in the Asia-Pacific region, excluding Japan. Menarini’s Menarini Asia-Pacific Holdings Pte. Ltd. subsidiary is solely responsible for the oral pan- histone deacetylase (HDAC) inhibitor in the licensed territory. ...